§ BIOTECHNOLOGY
USD · Biotechnology

ABBV

ABBVIE INC
USDSector · BiotechnologyMarket cap · $466.4BBeta · 0.20
LAST · MARKET CLOSE · NOV 20
283.54
−2.47 ▼ 0.86%PREV CLOSE · $286.01
§ 01 · PRICE
Price action
1D5D1M6MYTD1YMAX
OPEN 285.00HIGH 286.05LOW 279.8852W 190.75 — 267.47
EVENTSNOV 12 · SJR SELLSEP 30 · EARNINGS −0.1%
§ 02 · AC TAKE
Where we stand
LAST UPDATED TODAY

AbbVie (ABBV) carries a market cap of $466.4B and a price-to-earnings ratio of 74.0, meaning investors pay 74 dollars for each dollar of annual earnings.

The largest ownership bucket is other_unclassified at 31.8%, money our model could not sort into a style. Dealer banks, which facilitate trades for clients, hold 19.7%, and passive index funds hold 13.5%. Quality compounder holders, who buy steady earners and sit on them, hold 12.9%. Income_defensive holders have 3.1%, while growth_momentum is 0.0% and activists are 0.1%. Fast-moving money owns little of this stock. Institutional pressure reads Neutral at -0.02, so large holders show no strong lean either way. The market regime reads Risk-Off at -0.50, which indicates a cautious tape. A 74.0 multiple in a cautious market is the tension: the ownership mix suggests a steady shareholder base, but a high multiple leaves little cushion if sentiment sours. Caveats are real. 13F ownership data is 45 to 90 days old, so holders may have changed since. No short interest figure was supplied, and that data is reported only twice a month anyway. The supplied material carries no date for these figures. Everything here is historical, not predictive: it describes positioning, not what comes next. Watch whether the Risk-Off reading of -0.50 moves toward zero.

§ 03 · SIGNAL STACK · WHAT THE INPUTS SAY

13F FLOW
2192 increased/new, 1571 decreased/exited (13F)
AC 13F Analysis
INSIDER
−$12M
1 txn · 90d
SHORT INT
3.3 days to cover
FINRA
OPTIONS SKEW
Put/call ratio 2.35
CBOE
ANALYST
28 buy, 11 hold, 0 sell
Finnhub

§ 04 · FUNDAMENTALS · THE BOOKS

P/E74.0P/B94.44
EPS (TTM)3.56Dividend4.47%
◇ AC INTELLIGENCE

AbbVie (ABBV) carries a market cap of $466.4B and a price-to-earnings ratio of 74.0, meaning investors pay 74 dollars for each dollar of annual earnings. That is steep for a drugmaker. The data does not say which earnings figure sits behind it, so treat the multiple as a flag, not a verdict.

§ 05 · WHO OWNS IT
Top institutional holders
All holders →
FundShares% portΔ Q/Q
BlackRock150.7M0.6%−0%
VANGUARD CAPITAL MANAGEMENT LLC114.9Mn/an/a
State Street81.2M0.6%+0%
JPMORGAN CHASE & CO56.7Mn/a+8%
Vanguard Portfolio Management49.5Mn/an/a
Geode Capital Management46.7M0.6%+5%
◇ AC INTELLIGENCE

Top institutional owners for ABBV as of the most recent 13F reporting period (Q1 2026 · Period ended Mar 31). Δ Q/Q reflects share-count change vs. the prior filing — positive green means adding, negative red means trimming. Cross-reference with the ownership-mix bars below to see which strategy cohort is driving the flow.

§ 06 · WHO OWNS IT · BY STRATEGY

OTHER18.0% · 0 holders
OTHER31.8% · 3,693 holders
DEALER / BANK19.7% · 189 holders
PASSIVE / INDEX13.5% · 17 holders
QUALITY / COMPOUNDER12.9% · 46 holders
INCOME / DEFENSIVE3.1% · 86 holders
TACTICAL / MACRO0.3% · 7 holders
SYSTEMATIC / QUANT0.3% · 21 holders
DEEP VALUE0.3% · 5 holders
ACTIVIST0.1% · 1 holder
GROWTH / MOMENTUM0.0% · 1 holder
◇ AC INTELLIGENCE

Ownership mix by behavioral cohort. Top bars indicate which style of capital dominates the float — passive indexing, quality compounders, dealer/bank, systematic quant, etc. Big quality-compounder share means concentrated active conviction; heavy passive share means flows are dictated by index rebalances, not fundamentals.

§ 07 · INSIDER ACTIVITY · LAST 180 DAYS

DateInsiderActionShares$ value
NOV 12Stewart Jeffrey RyanSELL41K−$12M
◇ AC INTELLIGENCE

0 insider buys, 1 sell in the last 180 days. Scheduled 10b5-1 sales are pre-programmed and neutral; discretionary clusters are the tape worth reading. Cross-reference with the signal stack above for context.

§ 08 · COVERAGE · OUR RECENT NOTES

No notes mention ABBV yet.